AxoGen, Inc (NASDAQ:AXGN) SVP Shawn F. Mccarrey sold 10,000 shares of the stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $43.47, for a total value of $434,700.00. Following the transaction, the senior vice president now owns 33,057 shares of the company’s stock, valued at $1,436,987.79. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of AxoGen stock opened at $43.95 on Monday. AxoGen, Inc has a 12 month low of $13.95 and a 12 month high of $46.00. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.32 and a quick ratio of 2.81.
AxoGen (NASDAQ:AXGN) last announced its earnings results on Monday, April 30th. The medical equipment provider reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). AxoGen had a negative return on equity of 61.66% and a negative net margin of 18.83%. The company had revenue of $17.30 million during the quarter, compared to analysts’ expectations of $17.16 million. AxoGen’s revenue for the quarter was up 41.8% compared to the same quarter last year. equities analysts expect that AxoGen, Inc will post -0.38 EPS for the current year.
Institutional investors have recently made changes to their positions in the stock. Ladenburg Thalmann Financial Services Inc. boosted its holdings in AxoGen by 41.6% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,575 shares of the medical equipment provider’s stock valued at $167,000 after acquiring an additional 1,345 shares during the period. Princeton Capital Management LLC purchased a new position in AxoGen during the 1st quarter valued at about $183,000. Paloma Partners Management Co purchased a new position in AxoGen during the 4th quarter valued at about $215,000. Guggenheim Capital LLC purchased a new position in AxoGen during the 4th quarter valued at about $228,000. Finally, Gotham Asset Management LLC purchased a new position in AxoGen during the 4th quarter valued at about $249,000. Institutional investors own 71.02% of the company’s stock.
A number of research firms have recently weighed in on AXGN. ValuEngine upgraded AxoGen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target (up from $37.00) on shares of AxoGen in a report on Tuesday, May 1st. JMP Securities increased their price target on AxoGen from $34.00 to $43.00 and gave the stock a “market outperform” rating in a report on Tuesday, May 1st. Lake Street Capital set a $38.00 price target on AxoGen and gave the stock a “buy” rating in a report on Friday, March 2nd. Finally, William Blair began coverage on AxoGen in a report on Monday, February 5th. They set an “outperform” rating for the company. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. AxoGen presently has a consensus rating of “Buy” and a consensus target price of $35.57.
AxoGen Company Profile
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.